News & Views
Collaboration Speeds Commercialisation in Personalised Medicine
Aug 10 2018 Read 299 Times
A non-exclusive master collaboration agreement between Qiagen and SRL Inc, the largest clinical testing laboratory company in Japan, will accelerate implementation of companion diagnostic workflows following approval of the drugs and tests by Japan’s Pharmaceutical and Medical Devices Agency (PMDA). Several tests are expected to enter registration in Japan in the coming years.
Qiagen’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement and alignment of medical communication by the two companies and pharmaceutical partners. The agreement will cover a range of Qiagen companion diagnostics, including real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) solutions for Personalised Healthcare. Initial projects involve new drugs under development in Japan for solid tumours and leukemia.
“We are pleased to create this innovative program with SRL to close the time gap between new drug approvals and the availability of testing with companion diagnostics. Rapid implementation of personalised medicine solutions can benefit patients in many disease states, including cancer, with treatments guided by personalised genomic insights,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at Qiagen NV.
Shunichi Higashi, President and Chief Executive Officer of SRL, said: “We are excited to partner with QIAGEN to provide new companion diagnostic tests to patients who have urgent need for testing. Through QIAGEN´s numerous companion diagnostic development and commercial collaborations with pharmaceutical companies, we expect a significant increase in commercial testing requests in the upcoming years. Working with QIAGEN will help us to meet these future testing requests in the most timely way for the benefit of patients and healthcare providers in Japan.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Determination of heroin in street drug samples with printable surface enhanced Raman scattering (P-SERS) - Advances in Protein Sample Preparation: Centrifugation i...
View all digital editions
Jan 16 2019 Tokyo, Japan
Jan 28 2019 Dubai International Convention & Exhibition Centre
Jan 30 2019 Tokyo, Japan
Jan 31 2019 Paris, France
Feb 02 2019 Washington, DC, USA.